GM
Geoff Meacham Citigroup Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
63
Avg Return
Past Year
Past Year
15%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past 3 Months
Buy
64.3%
Hold
35.7%
Sell
0%
| Stock | Rating | Price Target |
Upside Downside |
Ratings 3 Months |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
Gilead Sciences
GILD
$145B
|
Buy
Maintained
| $135 |
15%
upside
| 1 | +13% |
0
%
| 8 Oct ‘25 4 days ago |
|
AbbVie
ABBV
$407B
|
Hold
Maintained
| $251 |
9%
upside
| 1 | -1.1% |
0
%
| 3 Oct ‘25 9 days ago |
|
Amylyx Pharmaceuticals
AMLX
$1.52B
|
Buy
Maintained
| $16 |
12%
upside
| 2 | +41% |
0
%
| 3 Oct ‘25 9 days ago |
|
Vertex Pharmaceuticals
VRTX
$105B
|
Buy
Maintained
| $575 |
41%
upside
| 1 | -8.7% |
0
%
| 2 Oct ‘25 10 days ago |
|
Avidity Biosciences
RNA
$7.26B
|
Buy
Maintained
| $65 |
31%
upside
| 1 | +11% |
0
%
| 15 Sep ‘25 27 days ago |
|
Vir Biotechnology
VIR
$806M
|
Buy
Upgraded
| $14 |
141%
upside
| 1 | +31% |
0
%
| 27 Aug ‘25 1 month ago |
|
Acumen Pharmaceuticals
ABOS
$130M
|
Buy
Maintained
| $9 |
321%
upside
| 1 | +37% |
0
%
| 25 Aug ‘25 1 month ago |
|
Amgen
AMGN
$156B
|
Hold
Maintained
| $310 |
7%
upside
| 2 | – |
–
| 6 Aug ‘25 2 months ago |
|
Biogen
BIIB
$21.5B
|
Hold
Maintained
| $135 |
8%
downside
| 1 | – |
–
| 1 Aug ‘25 2 months ago |
|
PTC Therapeutics
PTCT
$5.26B
|
Hold
Maintained
| $50 |
25%
downside
| 1 | – |
–
| 28 Jul ‘25 2 months ago |
|
CRISPR Therapeutics
CRSP
$6.65B
|
Buy
Maintained
| $78 |
7%
upside
| 1 | +33% |
0
%
| 22 Jul ‘25 2 months ago |
|
Royalty Pharma
RPRX
$15.6B
|
Buy
Maintained
| $42 |
17%
upside
| 1 | +1% |
0
%
| 22 Jul ‘25 2 months ago |
|